Carbonic anhydrase inhibitor sustained release intraocular drug delivery systems
US8591885B2 · kind B2 · utility
Assignee
Inventors
Key dates
| Filing date | Oct 31, 2007 |
| Grant date | Nov 26, 2013 |
| Priority date | — |
| Expiry date | Jun 30, 2030 |
Classification
- Technology area (CPC A)Human Necessities
- CPC primaryA61P29/00
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
Biocompatible intraocular drug delivery systems include a carbonic anhydrase inhibitor therapeutic agent and a polymeric component in the form of an implant, a microparticle, a plurality of implants or microparticles, and combinations thereof. The therapeutic agent is released in a biologically active form, for example, the therapeutic agent may retain its three dimensional structure when released into an eye of a patient, or the therapeutic agent may have an altered three. The implants may be placed in an eye to treat or reduce the occurrence of one or more ocular conditions, such as retinal damage, including glaucoma and proliferative vitreoretinopathy among others.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.